

July 23, 2025

The National Stock Exchange of India Limited
Exchange Plaza
Bandera Kurla Complex,
Bandra (E), Mumbai - 400 051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(SCRIP CODE 539871)

Subject: Press Release on unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025.

Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Please find enclosed herewith the Press Release on the unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025. We request you to please take the same on record

The same is also being made available on the Company's website <https://investor.thyrocare.com/>

This is for your information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited**,

Brijesh Kumar
Company Secretary and Compliance Officer
Encl. as above



Press Release

Thyrocare Technologies Limited reports revenue of INR 193.03 Cr in Q1FY26 with a growth of 23% YoY

Revenue

↑ **INR 193.03 Cr**
23% YoY

Normalized EBITDA

↑ **INR 63.35 Cr**
42% YoY

PAT

↑ **INR 38.06 Cr**
62% YoY

Navi Mumbai, July 23, 2025

Thyrocare Technologies Limited (hereinafter referred to as “**Thyrocare**” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2025.

Key highlights for Q1FY26:

- Consolidated revenue saw a YoY increase of 23%, driven by a 25% growth in Pathology and an 6% growth in Radiology.
- Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY.
- Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase.
- Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%.
- Consolidated EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%.
- Opened New Labs in Bhagalpur, Kashmir and Roorkee.

Consolidated income statement for Q1FY26, Q1FY25 and FY25:

| INR Crore | Quarter | | | Annual |
|---|---------|--------|-----|--------|
| | Q1FY26 | Q1FY25 | YoY | FY25 |
| Revenue from operations | 193.03 | 156.91 | 23% | 687.32 |
| Gross margin | 137.40 | 111.46 | 23% | 496.25 |
| Normalized EBITDA (before ESOP) | 63.35 | 44.73 | 42% | 209.94 |
| Reported EBITDA | 57.46 | 42.01 | 37% | 189.21 |
| Profit after tax incl. exceptional item | 38.06 | 23.47 | 62% | 90.02 |
| Key metrics | | | | |
| Gross margin% | 71% | 71% | | 72% |
| Normalized EBITDA% | 33% | 29% | | 31% |
| Reported EBITDA% | 30% | 27% | | 28% |
| PAT incl. exceptional item% | 20% | 15% | | 13% |

About Thyrocare:

Thyrocare Technologies Limited (NSE: THYROCare, BSE: 539871) is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Many laboratories and hospital brands all over India use the comprehensive test profile menu offered by Thyrocare.

Thyrocare has an extensive network of laboratories across PAN India. Thyrocare has a Quarterly active franchise count of 9,500+ and processed 46.9mn+ diagnostic and screening investigations in Q1FY26.

Thyrocare is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations including ISO 9001-2000 rating as early as 2001, which was upgraded to ISO 9001:2015 and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations in 2005.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Both the companies assume no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Brijesh Kumar
Company Secretary and Compliance Officer
brijesh.jha@thyrocare.com

+91 84229 45537



Company: Thyrocare Technologies Limited
CIN: L85110MH2000PLC123882
Website: www.thyrocare.com